- Home
- RUM vs NVCR Comparison
RUM vs NVCR Comparison
Compare RUM & NVCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | RUM | NVCR |
|---|---|---|
| Founded | 2013 | 2000 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Medical/Dental Instruments |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.1B | 2.0B |
| IPO Year | 2021 | 2015 |
Fundamental Metrics
Financial Performance| Metric | RUM | NVCR |
|---|---|---|
| Price | $7.69 | $15.88 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $27.14 |
| AVG Volume (30 Days) | ★ 5.2M | 1.0M |
| Earning Date | 11-09-2026 | 10-29-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 80.72 | 21.79 |
| EPS | ★ N/A | N/A |
| Revenue | $100,622,320.00 | ★ $655,353,000.00 |
| Revenue This Year | $142.21 | $10.76 |
| Revenue Next Year | $129.36 | $10.88 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | 5.38 | ★ 8.28 |
| 52 Week Low | $4.62 | $9.82 |
| 52 Week High | $10.60 | $21.45 |
Technical Indicators
Market Signals| Indicator | RUM | NVCR |
|---|---|---|
| Relative Strength Index (RSI) | 41.68 | 47.89 |
| Support Level | $6.86 | $14.93 |
| Resistance Level | $8.68 | $18.43 |
| Average True Range (ATR) | 0.50 | 0.57 |
| MACD | -0.16 | -0.02 |
| Stochastic Oscillator | 3.67 | 60.84 |
Price Performance
Historical ComparisonAbout RUM Rumble Inc.
RUM Group Inc focused is to maximize the power of human imagination through an independent technology ecosystem built on privacy, resilience, and an open alternative to Big Tech. Rumble gives human creativity a voice, a video and media platform built for creators and audiences who value free expression. Quake AI is a cloud and AI-infrastructure business, delivering the compute, data-center capacity, and blockchain infrastructure for the agentic era.
About NVCR NovoCure Limited
NovoCure Ltd is an oncology company with a proprietary platform technology in the United States. Its business involves the development, manufacture, and commercialization of Tumor Treating Fields (TTFields) devices, including Optune Gio and Optune Lua, for the treatment of solid tumor cancers. Its pipeline consists of Trident, Lunar-2, Panova-3, Metis, and other products and technologies for the treatment of Glioblastoma, Non-small cell lung cancer, and Pancreatic cancer. Geographically, the company derives the majority of its revenue from the United States and the rest from Germany, Japan, and other markets.